drugset / Trial / NCT00283036

APROVE : Irbesartan in Hypertension

NCT00283036

Phase 4 Completed 200 enrolled Sanofi Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Study objective : To compare efficacy and tolerability of posology adaptation of Irbesartan in ambulatory Hypertensive patients

Timeline

Start
2005-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule

Indications